Opinion statement
For the treatment of functional motor disorder, we recommend a three-stage approach. Firstly, patients must be assessed and given an unambiguous diagnosis, with an explanation that helps them understand that they have a genuine disorder, with the potential for reversibility. A key ingredient is allowing the patients to describe all of their symptoms as well as their ideas about what may be wrong. The patient should clearly understand that the positive diagnosis is based on the presence of typical signs (e.g., Hoover's sign for paralysis, entrainment test for tremor) that, in and of themselves, indicate the potential for reversibility. We suggest an approach that avoids the assumption that psychological stressors in the patient's life are causing the symptoms. The symptoms themselves are often the main stressor. Insisting that there must be others often leads to a frustrated doctor and an angry patient. Rather, at this initial stage, we encourage exploration of mechanisms – e.g., triggering of symptoms by pain, injury, or dissociation – and a discussion of how symptoms manifest as "abnormal motor programs" in the nervous system.
Secondly, further time spent exploring the diagnosis, treating comorbidity, and, in the context of a multidisciplinary team, experimenting with altered movements and behaviors may benefit some patients, without the need for more complex intervention.
Thirdly, some patients do require more complex treatment, often with a combination of physical rehabilitation and psychological treatments. Hypnosis, sedation, and transcranial magnetic stimulation may have a role in select patients.
Finally, although they have confidence in the diagnosis, many patients do not respond to treatment. Ultimately, however, patients with functional motor disorder may have much greater potential for recovery than health professionals often consider.
Similar content being viewed by others
References and Recommended Reading
• Of particular importance
Stone J, Edwards M. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. Neurology. 2012;79(3):282–4.
Kanaan R, Armstrong D, Wessely S. Limits to truth-telling: neurologists' communication in conversion disorder. Patient Educ Couns. 2009;77(2):296–301.
Stone J, Carson A, Duncan R, Roberts R, Warlow C, Hibberd C, et al. Who is referred to neurology clinics? –the diagnoses made in 3781 new patients. Clin Neurol Neurosurg. 2010;112(9):747–51.
Lempert T, Dieterich M, Huppert D, Brandt T. Psychogenic disorders in neurology: Frequency and clinical spectrum. Acta Neurologica Scandinavica 82(5):335-40
Parry AM, Murray B, Hart Y, Bass C. Audit of resource use in patients with non-organic disorders admitted to a UK neurology unit. J Neurol Neurosurg Psychiatry. 2006;77(10):1200–1.
Carson A, Stone J, Hibberd C, Murray G, Duncan R, Coleman R, et al. Disability, distress and unemployment in neurology outpatients with symptoms 'unexplained by organic disease'. J Neurol Neurosurg Psychiatry. 2011;82(7):810–3.
Anderson KE, Gruber-Baldini AL, Vaughan CG, Reich SG, Fishman PS, Weiner WJ, et al. Impact of psychogenic movement disorders versus Parkinson's on disability, quality of life, and psychopathology. Mov Disord. 2007;22(15):2204–9.
Stone J, Sharpe M, Rothwell PM, Warlow CP. The 12 year prognosis of unilateral functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry. 2003;74(5):591–6.
Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2013. doi:10.1136/jnnp-2013-305321.
Bogousslavsky J. Hysteria after Charcot: back to the future. Front Neurol Neurosci. 2011;29:137–61.
Splett T, Steinberg H. Treatment of hysteria in the 19th century–in which way did German psychiatrists view castration? Fortschr Neurol Psychiatr. 2003;71(1):45–52.
Poole NA, Wuerz A, Agrawal N. Abreaction for conversion disorder: systematic review with meta-analysis. Br J Psychiatry. 2010;197(2):91–5.
Nielsen G, Stone J, Edwards MJ. Physiotherapy for functional (psychogenic) motor symptoms: A systematic review. J Psychosom Res. 2013;75(2):93–102. doi:10.1016/j.jpsychores.2013.05.006. A systematic review of physiotherapy for FMD , showing a trend towards positive outcome, although evidence is limited.
Stone J, Carson AJ, Scharpe M. Psychogenic movement disorders: explaining the diagnosis. Psychogenic Movement Disorders and Other Conversion Disorders. Cambridge: Cambridge University Press; 2011. p. 254–66.
Health Improvement Scotland. (2012). Stepped care for functional neurological symptoms. HS Scotlland, Edinburgh. http://www.healthcareimprovementscotland.org/our_work/long_term_conditions/neurological_health_services/neurological_symptoms_report.aspx (accessed Dec 21 2013)
Jordbru AA, Smedstad LM, Klungsoyr O, Martinsen EW. Psychogenic gait disorder: A randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med. 2013. doi:10.2340/16501977-1246. The first randomised study of physiotherapy in FMD: An intervention of physical rehabilitation in a cognitive behavioural framework in 60 patients with FMD obtained positive results.
Edwards MJ, Stone J, Nielsen G. Physiotherapists and patients with functional (psychogenic) motor symptoms: A survey of attitudes and interest. J Neurol Neurosurg Psychiatry. 2012;83(6):655–8.
Czarnecki K, Thompson JM, Seime R, Geda YE, Duffy JR, Ahlskog J. Functional movement disorders: Successful treatment with a physical therapy rehabilitation protocol. Parkinsonism Relat Disord. 2012;18(3):247–51. A retrospective study to a one week physical therapy intervention suggesting a promising outcome of chronic FMD.
Dallocchio C, Arbasino C, Klersy C, Marchioni E. The effects of physical activity on psychogenic movement disorders. Mov Disord. 2010;25(4):421–5.
McCormack R, Moriarty J, Mellers JD, Shotbolt P, Pastena R, Landes N, et al. Specialist inpatient treatment for severe motor conversion disorder: a retrospective comparative study. J Neurol Neurosurg Psychiatry. 2013. doi:10.1136/jnnp-2013-305716.
Saifee TA, Kassavetis P, Parees I, Kojovic M, Fisher L, Morton L, et al. Inpatient treatment of functional motor symptoms: A long-term follow-up study. J Neurol. 2012;259(9):1958–63.
Ruddy R, House A. Psychosocial interventions for conversion disorder. Cochrane Database Syst Rev. 2005;4, CD005331.
Espay AJ, Goldenhar LM, Voon V, Schrag A, Burton N, Lang AE. Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord. 2009;24(9):1366–74.
McKenzie P, Oto M, Russell A, Pelosi A, Duncan R. Early outcomes and predictors in 260 patients with psychogenic nonepileptic attacks. Neurology. 2010;74(1):64–9.
Razvi S, Mulhern S, Duncan R. Newly diagnosed psychogenic nonepileptic seizures: health care demand prior to and following diagnosis at a first seizure clinic. Epilepsy Behav. 2012;23(1):7–9.
Carton S, Thompson PJ, Duncan JS. Non-epileptic seizures: patients' understanding and reaction to the diagnosis and impact on outcome. Seizure. 2003;12(5):287–94.
Baxter S, Mayor R, Baird W, Brown R, Cock H, Howlett S, et al. Understanding patient perceptions following a psycho-educational intervention for psychogenic non-epileptic seizures. Epilepsy Behav. 2012;23(4):487–93.
Hall-Patch L, Brown R, House A, Howlett S, Kemp S, Lawton G, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia. 2010;51(1):70–8.
Salmon P, Peters S, Stanley I. Patients' perceptions of medical explanations for somatisation disorders: qualitative analysis. BMJ. 1999;318(7180):372–6.
Friedman JH, LaFrance W. Psychogenic disorders: The need to speak plainly. Arch Neurol. 2010;67(6):753–5.
Duncan R. Psychogenic nonepileptic seizures: diagnosis and initial management. Expert Rev Neurother. 2010;10(12):1803–9.
Stone J, Wojcik W, Durrance D, Carson A, Lewis S, MacKenzie L, et al. What should we say to patients with symptoms unexplained by disease? The "number needed to offend". BMJ. 2002;325(7378):1449–50.
Edwards MJ, Stone J, Lang A. From Psychogenic Movement Disorder (PMD) to Functional Movement Disorder (FMD): It’s time to change the name. Movement Disorders. 2013. doi:10.1002/mds.25562.
Aybek S, Hubschmid M, Mossinger C, Berney A, Vingerhoets F. Early intervention for conversion disorder: neurologists and psychiatrists working together. Acta Neuropsychiatrica. 2012. doi:10.1111/j.1601-5215.2012.00668.x.
Hopp JL, LaFrance Jr WC. Cognitive behavioral therapy for psychogenic neurological disorders. Neurologist. 2012;18(6):364–72.
Baslet G, Hill J. Case report: Brief mindfulness-based psychotherapeutic intervention during inpatient hospitalization in a patient with conversion and dissociation. Clin Case Studies. 2011;10(2):95–109.
Sharpe M, Walker J, Williams C, Stone J, Cavanagh J, Murray G, et al. Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. Neurology. 2011;77(6):564–72.
Allen LA, Woolfolk RL, Escobar JI, Gara MA, Hamer RM. Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. Arch Intern Med. 2006;166(14):1512–8.
Kompoliti K, Wilson B, Stebbins G, Bernard B, Hinson V. Immediate vs. delayed treatment of psychogenic movement disorders with short term psychodynamic psychotherapy: Randomized clinical trial. Parkinsonism Relat Disord. 2013. doi:10.1016/j.parkreldis.2013.09.018.
Hinson VK, Weinstein S, Bernard B, Leurgans SE, Goetz CG. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism and Related Disorders. 2006;12(3):177–80.
Reuber M, Burness C, Howlett S, Brazier J, Grunewald R. Tailored psychotherapy for patients with functional neurological symptoms: a pilot study. J Psychosom Res. 2007;63(6):625–32.
Voon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. J Clin Psychiatry. 2005;66(12):1529–34.
Edwards MJ, Talelli P, Rothwell JC. Clinical applications of transcranial magnetic stimulation in patients with movement disorders. Lancet Neurol. 2008;7(9):827–40.
Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010;71(7):873–84.
Geraldes R, Coelho M, Rosa M, Severino L, Castro J, de Carvalho M. Abnormal transcranial magnetic stimulation in a patient with presumed psychogenic paralysis. J Neurol Neurosurg Psychiatry. 2008;79(12):1412–3.
Liepert J, Hassa T, Tuscher O, Schmidt R. Motor excitability during movement imagination and movement observation in psychogenic lower limb paresis. J Psychosom Res. 2011;70(1):59–65.
Liepert J, Shala J, Greiner J. Electrophysiological correlates of disobedience and feigning-like behaviour in motor imagery. Clin Neurophysiol. 2013. doi:10.1016/j.clinph.2013.09.013.
Pollak TA, Nicholson TR, Edwards MJ, David AS. A systematic review of transcranial magnetic stimulation in the treatment of functional (conversion) neurological symptoms. J Neurol Neurosurg Psychiatry. 2013. doi:10.1007/s13311-013-0246-x.
Garcin B, Roze E, Mesrati F, Cognat E, Fournier E, Vidailhet M, et al. Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders. J Neurol Neurosurg Psychiatry. 2013;84(9):1043–6. A study of 24 patients with functional movement disorders who were treated with a single session TMS and blindly assessed by means of video recordings.
Chastan N, Parain D. Psychogenic paralysis and recovery after motor cortex transcranial magnetic stimulation. Mov Disord. 2010;25(10):1501–4.
Shah BB, Zurowski M, Chen R, et al. Failure of motor cortex repetitive transcranial magnetic stimulation (rTMS) combined with suggestion in the treatment of chronic psychogenic movement disorders (PMDs): a pilot study. 15th International Congress of Parkinson’s Disease and Movement Disorders, Toronto, ON, Canada, 2011.
Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008–39.
Toglia JU, Izzo K. Treatment of myoclonic dystonia with transcutaneous electrical nerve stimulation. Ital J Neurol Sci. 1985;6(1):75–8.
Bending J, Cleeves L. Effect of electrical nerve stimulation on dystonic tremor. Lancet. 1990;336(8727):1385–6.
Tinazzi M, Farina S, Bhatia K, Fiaschi A, Moretto G, Bertolasi L, et al. TENS for the treatment of writer's cramp dystonia: a randomized, placebo-controlled study. Neurology. 2005;64(11):1946–8.
Maltete D, Verdure P, Roze E, Vidailhet M, Apartis E, Bellow F, et al. TENS for the treatment of propriospinal myoclonus. Mov Disord. 2008;23(15):2256–7.
Foley-Nolan D, Kinirons M, Coughlan RJ, O'Connor P. Post whiplash dystonia well controlled by transcutaneous electrical nervous stimulation (TENS): case report. J Trauma. 1990;30(7):909–10.
Withrington RH, Wynn Parry CB. Rehabilitation of conversion paralysis. J Bone Joint Surg (Br). 1985;67(4):635–7.
Atan C, Seckin U, Bodur H. Hysterical paralysis. Rheumatol Int. 2007;27(9):873–4.
Wojtecki L, Groiss S, Scherfeld D, Albrecht P, Pollok B, Elben S, et al. Transient improvement of psychogenic (proprio-)spinal-like myoclonus to electrical nerve stimulation. Mov Disord. 2009;24(13):2024–5.
Brierley H. The treatment of hysterical spasmodic torticollis by behaviour therapy. Behav Res Therapy. 1967;5(2):139–42.
Ferrara J, Stamey W, Strutt AM, Adam OR, Jankovic J. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosc. 2011;23(2):141–8.
Khalil TM, Abdel-Moty E, Asfour SS, Fishbain DA, Rosomoff RS, Rosomoff HL. Functional electric stimulation in the reversal of conversion disorder paralysis. Arch Phys Med Rehabil. 1988;69(7):545–7.
Fishbain DA, Goldberg M, Khalil TM, Asfour SS, Abdel-Moty E, Meagher B, et al. The utility of electromyographic biofeedback in the treatment of conversion paralysis. Am J Psychiatry. 1988;145(12):1572–5.
Simpson PM, Fouche PF, Thomas RE, Bendall JC. Transcutaneous electrical nerve stimulation for relieving acute pain in the prehospital setting: a systematic review and meta-analysis of randomized-controlled trials. Eur J Emerg Med. 2013. doi:10.1097/MEJ.0b013e328363c9c1.
Stone J, Hoeritzauer I, Brown K, Carson A. Therapeutic sedation for functional (psychogenic) neurological symptoms. J Psychosom Res. 2013. 10.1016/j.jpsychores.2013.10.003.
Medlin F, Aybek S, Berney A, Guedj E, Delaloye AB, Prior JO, et al. Psychogenic tetraparesis and bilateral upper limb dystonia, regressive under short propofol-induced sedation and during hepatic encephalopathy. Psychosomatics. 2012;53(5):485–8.
Van Nuenen BFL, Wohlgemuth M, Wong Chung RE, Abdo WF, Bloem BR. Acupuncture for psychogenic movement disorders: Treatment or diagnostic tool? Mov Disord. 2007;22(9):1353–5.
Zhang ZY, Yuan YM, Yan BW, Tian YQ, Wang W, Fan LM. An observation of 1316 cases of hysterical paralysis treated by acupuncture. J Tradit Chin Med. 1987;7(2):113–5.
Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993;43(2):349–52.
Baik JS, Han SW, Park JH, Lee MS. Psychogenic paroxysmal dyskinesia: The role of placebo in the diagnosis and management. Mov Disord. 2009;24(8):1244–5.
Edwards MJ, Bhatia KP, Cordivari C. Immediate response to botulinum toxin injections in patients with fixed dystonia. Mov Disord. 2011;26(5):917–8.
Shamy MCF. The treatment of psychogenic movement disorders with suggestion is ethically justified. Mov Disord. 2010;25(3):260–4.
Rommelfanger KS. Opinion: A role for placebo therapy in psychogenic movement disorders. Nat Rev Neurol. 2013;9(6):351–6.
Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5(12):e15591.
Lynoe N, Mattsson B, Sandlund M. The attitudes of patients and physicians towards placebo treatment–a comparative study. Soc Sci Med. 1993;36(6):767–74.
Dickes RA. Brief therapy of conversion reactions: an in-hospital technique. Am J Psychiatry. 1974;131(5):584–6.
Trieschmann RB, Stolov WC, Montgomery ED. An approach to the treatment of abnormal ambulation resulting from conversion reaction. Arch Phys Med Rehabil. 1970;51(4):198–206.
Shapiro AP, Teasell RW. Behavioural interventions in the rehabilitation of acute v. chronic non-organic (conversion/factitious) motor disorders. Br J Psychiatry. 2004;185:140–6.
Teasell RW, Shapiro AP. Strategic-behavioral intervention in the treatment of chronic nonorganic motor disorders. Am J Phys Med Rehabil. 1994;73(1):44–50.
Ward NS, Oakley DA, Frackowiak RS, Halligan PW. Differential brain activations during intentionally simulated and subjectively experienced paralysis. Cogn Neuropsychiatry. 2003;8(4):295–312.
Bell V, Oakley DA, Halligan PW, Deeley Q. Dissociation in hysteria and hypnosis: evidence from cognitive neuroscience. J Neurol Neurosurg Psychiatry. 2011;82(3):332–9.
Moene FC, Spinhoven P, Hoogduin KAL, Van Dyck R. A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type. Psychother Psychosom. 2002;71(2):66–76.
Moene FC, Spinhoven P, Hoogduin KA, van Dyck D. A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type. Int J Clin Exp Hypn. 2003;51(1):29–50.
Ferrara J, Jankovic J. Psychogenic movement disorders in children. Mov Disord. 2008;23(13):1875–81.
Faust J, Soman TB. Psychogenic movement disorders in children: Characteristics and predictors of outcome. J Child Neurol. 2012;27(5):610–4.
Compliance with Ethics Guidelines
Conflict of Interest
Jeannette M. Gelauff has received grant support from a BCN Groningen Scholarship.
Yasmine E.M. Dreissen has received grant support from the Princess Beatrix Fund for a trial on botulinum toxin in functional jerky movement disorders. These funds were paid to the AMC Medical Research BV in Amsterdam (Yasmine E.M. Dreissen’s salary is paid from this money). She has also had travel expenses paid by the Princess Beatrix Fund, and Ipsen Pharmaceuticals paid for a portion of the botulinum toxin used in the trial.
Marina A.J. Tijssen has received grant support from STW Technology Society (NeuroSIPE), Netherlands Organization for Scientific Research (NWO Medium), Fonds Nuts-Ohra, the Princess Beatrix Fund, the Gossweiler Foundation, Stichting Wetenschapsfonds Dystonie Vereniging, Ipsen, Allergan, and Medtronic. The funds were paid to the university (University of Amsterdam, and from 2012 onward, Rijksuniversiteit Groningen).
Jon Stone has received grant support from the NHS Scotland National Research Strategy Career Fellowship and the NIHR (as principal investigator); is employed by NHS Lothian; has regularly provided medicolegal expert witness testimony for negligence and personal injury cases; has received lecture honoraria from St. Louis Neurology, UK Tribunals Judiciary, Iceland Neurology Department (UCB), the Portuguese Movement Disorders (Novartis), Cork Neurology (UCB), the Movement Disorders Society, and the St. Louis Neurology Department; has received royalties from UpToDate; and runs a free self-help website for patients with functional motor disorders (www.neurosymptoms.org) mentioned in this article.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Movement Disorders
Jeannette M. Gelauff and Yasmine E.M. Dreissen contributed equally to this work
Rights and permissions
About this article
Cite this article
Gelauff, J.M., Dreissen, Y.E.M., Tijssen, M.A.J. et al. Treatment of Functional Motor Disorders. Curr Treat Options Neurol 16, 286 (2014). https://doi.org/10.1007/s11940-014-0286-5
Published:
DOI: https://doi.org/10.1007/s11940-014-0286-5